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AmyloidProtein misfolding and aggregation are the hallmark of a number of diseases including Alzheimer's disease,
Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and the prion diseases. In all cases,
a naturally-occurring protein misfolds and forms aggregates that are thought to disrupt cell function through
a wide range of mechanisms that are yet to be fully unraveled. Fourier transform infrared (FTIR) spectroscopy
is a technique that is sensitive to the secondary structure of proteins and has been widely used to investigate
the process of misfolding and aggregate formation. This review focuses on how FTIR spectroscopy and spec-
troscopic microscopy are being used to evaluate the structural changes in disease-related proteins both in
vitro and directly within cells and tissues. Finally, ongoing technological advances will be presented that
are enabling time-resolved FTIR imaging of protein aggregation directly within living cells, which can provide
insight into the structural intermediates, time scale, and mechanisms of cell toxicity associated with aggre-
gate formation. This article is part of a Special Issue entitled: FTIR in membrane proteins and peptide studies.
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Manydiseases involve themisfolding and aggregation of naturally oc-
curring proteins in the body. These aggregates disrupt cellular function
through a number of different mechanisms, often resulting in cell death
[1]. This process is most prevalent in neurodegenerative diseases [2,3].embrane proteins and peptide
rate, Bldg. 743, Brookhaven
1973-5000, USA. Tel.: +1 631
rights reserved.For example, Alzheimer's disease is characterized by the misfolding of
the amyloid beta (Abeta) protein, which leads to amyloid plaques,
whereas structural changes associated with hyperphosphorylation of
the tau protein leads to the formation of neuroﬁbrillary tangles. In
Parkinson's and Huntington's disease, aggregates of α-synuclein and
huntingtin are observed, respectively. A familial form of amyotrophic lat-
eral sclerosis (ALS) is characterized by tiny aggregates of copper-zinc su-
peroxide dismutase (SOD1). Prion diseases such as mad cow disease
(bovine spongiform encephalopathy), Creutzfeldt–Jakob disease, scrapie,
and chronic wasting disease are associated with the misfolding of the
prion protein, which becomes infectious in its aberrant form. Not all
protein-folding diseases occur in the central nervous system; other ex-
amples include cystic ﬁbrosis, type II diabetes, and multiple myeloma
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ary structure.
Fourier transform infrared spectroscopy (FTIR) has been shown to
be sensitive to the secondary structure of proteins, making it a valu-
able technique for studying protein aggregation. A protein's FTIR
spectrum has two prominent features, the Amide I (~1650 cm−1)
and Amide II (~1540 cm−1) bands, where the former arise primarily
from the C_O stretching vibration and the latter is attributed to the
N\H bending and C\N stretching vibrations of the peptide backbone
[5]. The frequency of the Amide I band is particularly sensitive to sec-
ondary structure based on different hydrogen-bonding environments
forα-helix, β-sheet, turn, and unordered conformations. For example,
α-helices and β-sheets have Amide I vibrational frequencies at ap-
proximately 1655 and 1630 cm−1, respectively [6,7]. The vibrational
frequency of an aggregated protein falls around 1620–1625 cm−1
due to the distinct hydrophobic environment [8]. For most proteins,
a mixture of secondary structures exists; thus, the Amide I band rep-
resents a combination of these components (Fig. 1). As a ﬁrst approx-
imation, the Amide I band can be curve-ﬁt to predict a protein's
secondary structure, or database approaches based on crystallograph-
ic information have also been used [9].
Beyond the examination of protein secondary structure in vitro, FTIR
spectroscopic microscopy can also be used to directly study protein
misfolding and aggregation within cells and tissues. Protein aggregates
are typically very small, where initial oligomers form at the nanoscale
and the larger aggregates are only 20–30 μm in size. In addition, the
spectral differences associated with changes in protein conformation
are subtle, requiring spectra with a high signal-to-noise (S/N) ratio.
These challenges have been addressed recently by taking advantage of
the high brightness of a synchrotron infrared source, where protein
misfolding and aggregation have been examined directly within
diseased tissue in Alzheimer's disease [8,10–12], Parkinson's disease
[13], Huntington's disease [14], amyotrophic lateral sclerosis [15], and
scrapie [16–18].
In this review, we will describe how FTIR spectroscopy and mi-
croscopy have been used to examine protein misfolding and aggrega-
tion both in vitro and in situ. The challenges associated with data
collection and spectral interpretation will be discussed along with re-
cent technological developments and opportunities for future studies.
2. FTIR spectroscopy of protein structure in vitro
Since the Amide I band is sensitive to protein secondary structure,
FTIR spectroscopy is frequently used to study the process of protein
misfolding and aggregation in vitro. Due to unique hydrogen bonding
environments for the different secondary structure elements, shiftsFig. 1. FTIR spectrum of a typical protein illustrating the Amide I and Amide II bands at
~1650 cm−1 and ~1540 cm−1, respectively. (Inset) Expanded view of the Amide I
band, which can be deconvolved into its secondary structure components.are observed in the frequency of the Amide I band [6,19]. And by
studying protein structure in vitro, the effects of temperature, pH, sol-
vent, and protein conformation can be systematically examined.
The major difﬁculty with measuring FTIR spectra of proteins in
water arises from the strong water bending mode that overlaps the
Amide I vibrational mode. Thus, transmission measurements of
protein solutions are typically performed in D2O, where the O\D
bending mode is shifted to lower frequency (Fig. 2). Alternatively,
spectra can be collected in water with very thin pathlengths
(b10 μm), but this requires a higher protein concentration. For FTIR
spectroscopy of protein solutions in D2O, protein concentrations of
0.5–10 mM are common. Protein solutions are placed in a sandwich
cell between two IR-transparent windows (typically CaF2 or BaF2),
separated by a thin spacer (typically 25–50 μm thick). The reference
(background) spectrum is collected through the buffer solution.
Secondary structure analysis of the Amide I band has been
performed in a number of ways, including second derivatives, Fourier
self-deconvolution, curve-ﬁtting, and neural networks [6,7,9,19–23].
Most frequently, second-derivative analysis is used to identify the
frequencies of the underlying spectral components. Then spectral
deconvolution (i.e. curve-ﬁtting) is performed on the Amide I band to
deﬁne the intensities of the components (see Fig. 1). While absolute
secondary structure quantiﬁcation can be done, the best results are
achieved when structural changes are studied as a function of an exter-
nal perturbation, as has been demonstrated for the amyloid-beta
protein [24].2.1. Alzheimer's disease
Protein misfolding and aggregation have been studied extensively
in vitro using FTIR spectroscopy. For example, Alzheimer's disease
(AD) is a neurodegenerative disorder characterized by the accumula-
tion of senile plaques and neuroﬁbrillary tangles in gray matter areas
of the brain. Plaque formation is brought about by the transformation
of a small peptide known as amyloid-beta (Abeta) from a soluble
form through an oligomeric intermediate to an aggregated, ﬁbrillary
structure [25].
The mechanism behind the structural changes and toxicity of Abeta
during aggregate formation has been the subject of numerous in vitro
studies. The seminal studies utilized circular dichroism (CD) and NMR
to show the structural conversion of Abeta from a solubleα-helical pro-
tein to a ﬁbrillar β-sheet protein [26–29]. More recently, FTIR spectros-
copy has been used to study the speciﬁc alignment of β-sheet strands
within Abeta ﬁbrils. Using isotopically-labeled Abeta(16–22), Petty
and coworkers showed conclusively that the β-sheets are antiparallel
and in alignment across all strands. This realignment of the peptide
strands is important for therapeutics because they form more stable
amyloid ﬁbrils [30].Fig. 2. FTIR transmission spectra of H2O and D2O. As can be seen, an O\H bending
mode overlaps with the protein Amide I band at ~1650 cm−1. With deuteration, the
O\D bending mode falls at a lower frequency (~1225 cm−1), increasing the IR trans-
mission in the region of the Amide I band and enabling better background (i.e. solvent)
subtraction.
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cursor protein (APP), it has been suggested that oligomeric Abeta
forms pore-like structures in lipid membranes that disrupt ion
homeostasis and cause cell death. Using FTIR spectroscopy, Abeta
oligomers have been shown to exhibit an antiparallel β-sheet struc-
ture, where the spectrum was very similar to that of bacterial outer
membrane porins [31]. With polarized attenuated total internal
reﬂection FTIR (ATR-FTIR) spectroscopy, it was also shown that mem-
branes promote β-sheet formation [32] and that membranes containing
oxidatively damaged phospholipids accumulated Abeta signiﬁcantly
faster than membranes containing only unoxidized or saturated phos-
pholipids [33].
In addition to the Abeta protein, FTIR spectroscopy has also been
instrumental in understanding the structural conformation of
the tau protein — a neuronal microtubule protein that becomes
hyperphosphorylated and forms paired helical ﬁlaments (PHFs) in
the AD brain. Conﬂicting views on the structure of the tau “tangles”
have been proposed, ranging from mainly α-helical structure to
mainly β-sheet, or a mixture of mostly random coil and β-sheet.
In vitro FTIR analysis showed that the soluble tau protein is a natively
unfolded protein dominated by random coil structure, whereas
Alzheimer PHFs show an increase in the level of β-structure [34,35].
The results support a model in which the repeat domain of tau (which
lies within the core of PHFs) adopts an increasing level of β-structure
during aggregation, whereas the N- and C-terminal domains projecting
away from the PHF core are mostly random coil.2.2. The prion diseases
The transmissible spongiform encephalopathies (TSEs), also termed
prion diseases, are a group of fatal, neurodegenerative diseases charac-
terized by themisfolding and accumulation of the prion protein (PrPSc).
This protein differs in secondary structure from its normal, cellular
isoform (PrPC), which is physiologically expressed mostly by neurons.
Importantly, prions are considered infectious because PrPSc is capable
of causing the normal PrPC protein to misfold into the disease-related
form, resulting in a catalytic process that produces a large amount of
aberrant protein. Thus, only a small amount of PrPSc is needed to initiate
disease, which is always fatal.
Scrapie is a prion disease ﬁrst described in the 18th century in
sheep and goats and a rodent model has been established to study
the pathogenesis and pathology of the disease. FTIR spectroscopy of
the isolated prion protein showed that PrPC was predominantly
α-helical in structure whereas PrPSc was primarily β-sheet [16]. Sim-
ilar structural differences were observed in scrapie-infected ganglia,
although not all neurons were affected [18].
Early diagnosis of the prion diseases is paramount to successful
treatment. FTIR spectroscopy and artiﬁcial neural networks were used
to screen blood serum from terminal scrapie-infected hamsters and
consistently yielded test sensitivities and speciﬁcities of 97% and 100%,
respectively [36]. A similar classiﬁcation algorithm was also developed
for terminal bovine spongiform encephalopathy (BSE)with a sensitivity
and speciﬁcity of 96% and 92%, respectively [37]. And more recently,
preclinical scrapie (100 days post infection) was reliably detected
from blood serum [38].
Another substantial challenge in prion research is the discrimina-
tion of different TSE strains that cause scrapie, BSE, or Creutzfeldt–
Jakob disease. In a study by Thomzig and coworkers, four different
isolates of hamster-adapted scrapie were infected into Syrian ham-
sters and probed by FTIR spectroscopy [39]. Results showed different
secondary structures between the TSE agents, even in cases where
immunobiochemical typing failed to detect structural differences.
Thus, FTIR spectroscopy may provide a promising analytical tool for
molecular strain typing without antibodies and without restrictions
to speciﬁc TSEs or mammalian species.2.3. Parkinson's disease
Parkinson's disease is a neurodegenerative disorder characterized by
the formation of abnormal protein aggregates called Lewy bodies in the
neurons of the brain. The principle component of Lewy bodies is the
α-synuclein protein, which is a protein of unknown function that is nor-
mally found as a soluble, unordered structure in the cytosol of neurons.
There is considerable debate about themechanismbehind the ﬁbril-
lation of α-synuclein during Lewy body formation and subsequent dis-
ease toxicity. FTIR and CD spectroscopy have shown that α-synuclein
ﬁbrils are antiparallel β-sheet in structure, similar to ﬁbrillar Abeta
[40]. Fibrillation likely takes place via long-range intramolecular inter-
actions between the N- and C-termini of α-synuclein [41]. Two homol-
ogous proteins, β- and γ-synuclein, are also natively unfolded but do
not form ﬁbrils unless exposed to metal ions such as Cu2+, Zn2+, and
Pb2+ [42]. It has also been shown by FTIR spectroscopy that mixtures
of the synucleins can prevent the ﬁbrillation of α-synuclein [43].
2.4. Huntington's disease
Huntington's disease is a neurodegenerative disorder that is caused
by a geneticmutation of theHuntingtin gene (HTT),which codes for the
huntingtin protein. More speciﬁcally, Huntington's disease is a trinucle-
otide repeat disorder, where the HTT gene codes for a long chain of glu-
tamine residues – called the polyQ region – in the huntingtin protein.
Disease symptoms occur when the polyQ region is longer than ~36
residues.
The disease is characterized by neuronal inclusion bodies that are
primarily composed of aggregates formed from fragments of polyQ
region of the mutant huntingtin protein. Using FTIR spectroscopy of
the puriﬁed huntingtin fragments, results showed that globular and
protoﬁbrillar intermediates participated in the genesis of mature
ﬁbrils [44]. The intermediates were high in β-sheet structure. More-
over, Congo Red – a dye commonly used to assay for amyloid ﬁber
formation – prevented the assembly of mature huntingtin ﬁbrils, pos-
sibly by binding to the β-structure of the protoﬁbril.
3. FTIR microspectroscopy of protein structure in ﬁxed cells
and tissues
FTIR microscopes have been used to examine the composition of
biological cells and tissues for over 20 years. However, the long wave-
lengths of infrared light result in diffraction effects that limit the spa-
tial resolution that can be achieved to 2–10 μm in the mid-infrared
region. In addition, the brightness of conventional thermal (globar)
IR sources are inherently limited near the diffraction limit.
Examination of protein misfolding and aggregation presents a
unique challenge for FTIR spectroscopic microscopy (FTIRM) because
the aggregates are typically very small, i.e. initial oligomers form at
the nanoscale and the larger aggregates are only 20–30 μm in size.
In addition, the spectral differences associated with changes in pro-
tein conformation are subtle, requiring spectra with a high S/N
ratio. Over recent years, dramatic improvements have been realized
through the utilization of a synchrotron infrared source, which is
100–1000 times brighter than a conventional thermal source [45].
This brightness advantage is not because the synchrotron produces
more power, but because the effective source size is small and the
light is emitted into a narrow range of angles. The high brightness
(i.e. ﬂux density) of the synchrotron source allows smaller regions
to be probed with an acceptable S/N ratio [46,47].
One of the earliest uses of a synchrotron-based IR microscope was
to examine the secondary structure of Abeta directly within the brain
tissue of an Alzheimer's case [10]. Interestingly, these ﬁndings re-
vealed spectral differences between the in vitro, solution-state pro-
tein and the in situ, amyloid structure of AD plaques, indicating that
the misfolding of Abeta depends on factors present in brain tissue
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the density of dense-core plaques was approximately 1.5 times higher
than the surrounding brain tissue [12] and the Amide I maximum was
observed at 1623 cm−1 [8], signiﬁcantly lower than Abeta aggregates
in solution, and characteristic of aggregated protein in a highly hydro-
phobic environment (Fig. 3). In contrast, diffuse plaques were not asso-
ciated with IR detectable changes in protein secondary structure [11].
The misfolding and aggregation of the infectious prion protein
have also been studied in the dorsal root ganglia of a hamster
model of scrapie. Synchrotron-based FTIRM was used to show that,
at pre-clinical time points, the scrapie-infected animals exhibited a
signiﬁcant increase in protein expression, but the β-sheet protein
content was signiﬁcantly lower than controls, suggesting that the
pre-clinical stages of scrapie were characterized by an overexpression
of proteins low in β-sheet content [17,18]. As the disease progressed,
the β-sheet content increased signiﬁcantly but immunostaining
conﬁrmed that this increase was partly – but not solely – due to the
formation of PrPSc in the tissue and indicated that other proteins high
in β-sheet were produced, either by overexpression or misfolding
(Fig. 4). These dramatic changes in protein content and structure,
especially at pre-clinical time points, emphasize the possibility for iden-
tifying other proteins involved in early pathogenesis, which are impor-
tant for a further understanding and early diagnosis of the disease.
Other FTIRM studies have examined subcellular protein composi-
tional changes in tissue but not speciﬁcally focusing on aggregate for-
mation. For example, the protein composition in the substantia nigra
in Parkinson's disease revealed signiﬁcant protein structural changes
in the nerve cell bodies prior to the formation of Lewy body aggre-
gates, suggesting that disturbances of normal functioning neurons ap-
pear well before their morphological atrophy [13]. In a rat model of
Huntington's disease, misfolding of the huntingtin protein was
evidenced by the appearance of β-sheet-rich structures in striatal
neurons [14]. At the same time, other spectral regions demonstrated
a reduction in unsaturated lipid content and an increase protein
phosphorylation, which are consistent with myelination deﬁciency
and early pro-apoptotic events, respectively, and demonstrate that a
range of compositional changes can be assessed and correlated with
protein misfolding in situ.
4. FTIR spectroscopic imaging of protein structure in living cells
As can be seen, FTIR spectroscopy and microspectroscopy have
been widely used to examine the mechanisms behind the pathology
of a wide range of protein-folding diseases. These studies have been
performed in vitro, in cell culture, and in situ on histological tissue
sections. However to date, the vast majority of these experiments
have been performed on static systems.Fig. 3. FTIRM of amyloid plaques in a PSAPP mouse model of Alzheimer's disease. (A) Thioﬂa
showing the distribution of protein measured by the Amide II band. (C) Infrared spectra coll
of protein in the center of a plaque (black) and the surrounding tissue (red). The increase in
plaque (black) spectrum. All scale bars are 5 μm. With permission from [12].In the ﬁeld of neurodegenerative protein-folding diseases, a num-
ber of recent studies suggest that the neuron toxicity arises from the
initial oligomeric species, rather than the larger protein plaques. The
mechanism of oligomer toxicity is still under debate, but includes
the formation of transmembrane pores that disrupt ion transport
through cells. Pore-forming oligomeric structures have been de-
scribed with Abeta in Alzheimer's disease [48] and α-synuclein in
Parkinson's disease [49]. Over the years, a number of static studies
have demonstrated that FTIR spectroscopy can be used to study the
formation of amyloid in vitro. However, given the evidence that the
oligomeric state is likely the toxic species, future in vitro experiments
are likely to include time-resolved measurements in order to study
the initial misfolding, oligomerization, and ﬁbrillization of protein ag-
gregates. One such example used a sub-millisecond pH jump to mon-
itor the kinetics of the structural transition of Abeta(1–28) and
showed an initial rapid transition from a random coil to an oligomeric
β-sheet conformation followed by a second slower transition, which
yielded larger aggregates [50].
Similar studies are being imagined in cell culture, where protein
misfolding and aggregation are probed in real time. However, experi-
mental challenges such as overcoming the water absorption and maxi-
mizing the subcellular spatial resolution must be addressed. One
promisingmethod for achieving these goals is synchrotron-based infra-
red imaging with a full-ﬁeld focal plane array (FPA) detector. By utiliz-
ing a highmagniﬁcation IRmicroscope objective, the pixel resolution of
the detector can be increased dramatically, enabling pixel oversampling
and image deconvolution. However, with a conventional thermal IR
source, the ﬂux incident on each pixel may bemore than 100× smaller,
limiting the spectral quality [51]. The ~1000-fold brightness of the syn-
chrotron source improves the S/N ratio and has recently been used to
demonstrate sub-micron spatial resolution [52]. Thus, by taking advan-
tage of the synchrotron-based full-ﬁeld imaging approach, spectra can
be collected rapidly at high resolution, providing time-resolved images
of small structural changes over time.
In addition to improvements in spatial resolution and spectral
quality, widespread adoption of time-lapsed FTIR imaging (FTIRI)
requires the development of environmental chambers that are compat-
ible with the stringent requirements of the sample and IR microscope
optics. In particular, high-magniﬁcation Schwarzschild objectives have
short working distances that are typically less than a few millimeters,
and high numerical apertures that necessitate wide opening angles.
For biological cells, viabilitymust bemaintained by carefully controlling
the atmosphere, pH, and temperature within the chamber. Moreover,
the path length of the cell must be limited to b10 μm to allow for the
transmission of the IR beam through the aqueous media.
Ongoing developments of versatile chambers for in vivo FTIRI are
underway. For example, one chamber design uses thin diamond ﬁlmvin S-stained brain tissue showing three plaques. (B) Infrared image of the same tissue
ected from the areas marked with asterisks in (A) and (B), showing the relative amount
β-sheet content within the plaques is evident from the shoulder at ~1625 cm−1 in the
Fig. 4. FTIRM of the misfolded prion protein in a hamster model of scrapie showing results from a preclinical stage 100 days post infection (left column, 100 dpi) and at the ﬁrst
clinical signs of the disease (right column, fcs). Photomicrographs of the areas investigated with FTIRM are shown in the 1st row (unstained) and 2nd row (3F4-antibody stained
for the prion protein). The β-sheet and α-helix distributions are represented in the 3rd and 4th rows, respectively. At the earliest stages, some areas show high β-sheet as well as
high α-helix (*), which was not observed at the terminal stage. Areas with misfolded prion protein deposition as seen in the 3F4 stained sections showed elevated β-sheet (arrows),
while some areas showed high β-sheet but no aggregate deposition (arrowheads). All scale bars are 20 μm. With permission from [17].
2343L.M. Miller et al. / Biochimica et Biophysica Acta 1828 (2013) 2339–2346as windows, which are IR and visible light transparent, to aid in mini-
mizing the chamber thickness [53]. Others have used lithography to
pattern spacers of precise thickness onto calcium ﬂuoride windows
[54] and microﬂuidics to ﬂow media to the cells [55]. Additionally,
modiﬁcations have been made to commercially available ﬂow cells to
accommodate the needs of live cells with thinner spacers and micro-
patterned channels for ﬂow [56]. The use of attenuated total internal
reﬂectance (ATR), a technique that can improve the spatial resolution
by taking advantage of ATR crystals with a high index of refraction,
has also been implemented to study cancer cell growth [57,58]. In a
more recent study, the ATR crystal was attached to the IR objective
allowing data to be takendirectly froma Petri dish [59]. These chambersvary signiﬁcantly in design, but they allmaintain a lowproﬁle to accom-
modate small working distances and minimize water absorption, and
they ﬂow nutrients to the cells.
To demonstrate the coupling of an FTIR-compatible environmen-
tal chamber with a full-ﬁeld FPA IR detector, we have recently
performed time-lapsed infrared imaging of aggregate formation in a
cell culture model of amyotrophic lateral sclerosis (ALS). Speciﬁcally,
ALS is a neurodegenerative disease affecting the motor neurons of the
spinal cord. While most ALS cases are sporadic with no known cause,
some are linked to mutations in the antioxidant protein copper-zinc
superoxide dismutase (SOD1), which is associated with the formation
of small SOD1 aggregates in motor neurons. Interestingly, there are
2344 L.M. Miller et al. / Biochimica et Biophysica Acta 1828 (2013) 2339–2346over 166 individual mutations that have been shown to cause the for-
mation of SOD1 aggregates in motor neurons [60,61].
It is widely hypothesized that the SOD1 aggregates are comprised of
immature SOD1 protein, i.e. prior to metallation or post-translational
modiﬁcation. This hypothesis is primarily based on the high stability
of many of the holo-SOD1 mutations, making them unlikely to aggre-
gate once they are metallated [62]. Additional experiments have
shown that detergent-insoluble SOD1 aggregates extracted from mice
overexpressing human SOD1 mutations lack the post-translational
modiﬁcations [63] and do not contain the copper and zinc ions [64]
expected of a mature protein. In vitro studies using FTIR spectroscopy
have shown that both metallated and apo-SOD1 showed similar
changes to the natural β-sheet structure of the protein, regardless of
the aggregation method [65]. It has also been shown that disulﬁde-
reduced SOD1 readily induces oligomerization under physiologically
relevant conditions [66]. In addition, there is a wide range of aggrega-
tion propensities among the numerous disease-conferring SOD1 muta-
tions, and to date, no common factor has been found to predict the rate
of aggregation of a given mutation based on its known biochemical and
biophysical properties [67]. Despite many extensive studies on SOD1
aggregation, the mechanism(s) of aggregation remain unclear.
In addition to understanding protein aggregation, the process by
which aggregation is associated with neuron death remains illusive
and necessitates more in vivo studies. In particular, it is possible that
toxicity arises due to pore-forming oligomers analogous to those de-
scribed for Abeta in Alzheimer's disease [48] and α-synuclein in
Parkinson's disease [49]. The transmembrane pore structures are rich
in antiparallel β-sheet structure. Alternatively or in conjunction, ﬁbril
formationmay (also) be the culprit, which can be identiﬁed by the pres-
ence of parallel β-sheet structures. Since FTIR spectroscopy can readilyFig. 5. Time-lapsed FTIR imaging of CHO-K1 cells transiently transfected to overexpress the
~12 cells showing a positive transfection in 2 cells as identiﬁed by the yellow-green ﬂuoresc
living cells in a FTIR-compatible incubator at 12, 14, and 16 h post transfection. False color
β-sheet structure. As can be seen, this ratio decreases with time, indicating an increas
pore-forming oligomeric structures. (Bottom) FTIR spectra from the transfected (red) and n
formation in the transfected cells. All scale bars are 10 μm.distinguish parallel vs. antiparallel β-sheet structure [31], time-lapsed
FTIRI of SOD1 aggregation can provide insight into the structural inter-
mediates, time scale, and mechanism(s) of cell toxicity associated with
aggregate formation.
In cell culture, transient transfection has been used to overexpress
mutant SOD1 and form protein aggregates [67]. In order to visualize
the aggregates, SOD1 is co-expressed with yellow ﬂuorescent protein
(YFP) [68]. Results have shown different aggregation patterns and
time scales that depend upon the speciﬁc mutation, suggesting that
multiple misfolding pathways may exist [67].
Chinese hamster ovary (CHO-K1) cells were transfected to express
the mutant G37R SOD1-YFP with Lipo-D 293 transfection reagent.
The G37R mutation is located in the β-barrel and forms a moderate
amount of punctuate aggregates within 24 h of transfection [67].
Transfected cells were imaged at Beamline U10B at the National Syn-
chrotron Light Source (NSLS) at Brookhaven National Laboratory
using a Bruker Hyperion 3000 FTIR microscope equipped with a
128×128 pixel focal plane array detector. The cells were grown on
calcium ﬂuoride windows and transfected in the Petri dish in a con-
ventional incubator. Ten hours after the transfection was initiated,
the cells were transferred to custom FTIR-compatible incubator and
ultra-buffered (20 mM HEPES) F12K medium was circulated through
the ﬂow cell. A ﬁeld of approximately twelve cells was selected based
on the presence of YFP ﬂuorescence and FTIR images were taken
every hour from 11 to 16 h post-transfection.
Fig. 5 shows the visible and epiﬂuorescence images of SOD1-YFP
after 10 h, showing two transfected cells as indicated by the green ﬂuo-
rescence. FTIR spectra of the transfected (green) vs. non-transfected
(colorless) cells after 16 h shows a shift in the Amide I band to higher
frequency, suggesting an increase in antiparallel β-sheet structure.mutant, G37R-SOD1, over the course of 16 h. (Top row) Photomicrographs of a ﬁeld of
ence from the fusion tag, YFP, and outlined in red. (Middle row) FTIRI images from the
images show the ratio of 1630/1695 cm−1, which represents the parallel/antiparallel
e in the antiparallel β-sheet structure over time, which suggests the formation of
on-transfected (black) cells, also illustrating an increase in the antiparallel β-sheet con-
2345L.M. Miller et al. / Biochimica et Biophysica Acta 1828 (2013) 2339–2346FTIR images of the transfected cells conﬁrm the development of antipar-
allel β-sheet structure through a decrease in the 1630/1695 cm−1 ratio
over time, which can be observed as a shift from red/yellow to blue
pixels in the false-color image (Fig. 5). In contrast, the protein structure
in the surrounding non-transfected cells remains relatively constant.
Thus, the initial stages of aggregate formation in the G37A mutant
reveal a spectral signature that is consistent with the formation of
pore-forming oligomeric structures. Moreover, it is also likely that the
antiparallel β-sheet structure is an intermediate conformation for ﬁbril
formation. Further studies at longer time scales and with other SOD1
mutants will be needed to provide a complete picture of the folding in-
termediates and pathway to cell toxicity in SOD1-ALS.
5. Conclusion and outlook
In summary, FTIR spectroscopy and microspectroscopy have been
an integral part of understanding the mechanisms behind protein
misfolding diseases including Alzheimer's disease, Parkinson's disease,
Huntington's disease, the prion diseases, and amyotrophic lateral sclero-
sis. The ﬁeld is expected to continue its growth by incorporating new in
vivo and imaging technologies for time-resolved FTIR studies of protein
oligomerization, ﬁbril formation, and aggregation. In the future, we
expect that continued advances in FTIR spectroscopy and imaging, com-
bined with other spectroscopic methods, will lead to an improved un-
derstanding, diagnosis, and treatment of protein-folding diseases.
Acknowledgements
We thank Dr. David Borchelt (University of Florida College of Medi-
cine) for providing the SOD1 cDNA used for the time-lapsed FTIR imag-
ing study of G37R-SOD1 aggregation. The National Synchrotron Light
Source is supported by the US Department of Energy under Contract
No. DE-AC02-98CH10886. Beamline U10B at the NSLS was supported
by the National Institutes of Health grant RR23782.
References
[1] In: M. Ramirez-Alvarado, J.W. Kelly, C.M. Dobson (Eds.), Protein Misfolding
Diseases: Current and Emerging Principles and Therapies, Wiley Publishers, 2010.
[2] C.A. Ross,M.A. Poirier, Protein aggregation and neurodegenerative disease, Nat.Med.
10 (2004) S10–S17, (Suppl.).
[3] C.A. Ross, M.A. Poirier, Opinion: what is the role of protein aggregation in
neurodegeneration? Nat. Rev. Mol. Cell Biol. 6 (2005) 891–898.
[4] F.E. Cohen, J.W. Kelly, Therapeutic approaches to protein-misfolding diseases,
Nature 426 (2003) 905–909.
[5] P.I. Haris, F. Severcan, FTIR spectroscopic characterization of protein structure in
aqueous and non-aqueous media, J. Mol. Catal. B: Enzym. 7 (1999) 207–221.
[6] D.M. Byler, H. Susi, Examination of the secondary structure of proteins by
deconvolved FTIR spectra, Biopolymers 25 (1986) 469–487.
[7] E. Goormaghtigh, J.M. Ruysschaert, V. Raussens, Evaluation of the information con-
tent in infrared spectra for protein secondary structure determination, Biophys. J.
90 (2006) 2946–2957.
[8] L.M. Miller, Q. Wang, T.P. Telivala, R.J. Smith, A. Lanzirotti, J. Miklossy, Synchrotron-
based infrared and X-ray imaging shows focalized accumulation of Cu and Zn
co-localized with beta-amyloid deposits in Alzheimer's disease, J. Struct. Biol. 155
(2006) 30–37.
[9] R.W. Sarver, W.C. Krueger, Protein secondary structure from Fourier-transform
infrared-spectroscopy — a data-base analysis, Anal. Biochem. 194 (1991) 89–100.
[10] L.P. Choo, D.L. Wetzel, W.C. Halliday, M. Jackson, S.M. LeVine, H.H. Mantsch, In situ
characterization of beta-amyloid in Alzheimer's diseased tissue by synchrotron
Fourier transform infrared microspectroscopy, Biophys. J. 71 (1996) 1672–1679.
[11] M. Rak, M.R. Del Bigio, S. Mai, D. Westaway, K. Gough, Dense-core and diffuse Abeta
plaques in TgCRND8 mice studied with synchrotron FTIR microspectroscopy,
Biopolymers 87 (2007) 207–217.
[12] A.C. Leskovjan, A. Lanzirotti, L.M. Miller, Amyloid plaques in PSAPP mice bind less
metal thanplaques in humanAlzheimer's disease, NeuroImage 47 (2009) 1215–1220.
[13] M. Szczerbowska-Boruchowska, P. Dumas, M.Z. Kastyak, J. Chwiej, M. Lankosz, D.
Adamek, A. Krygowska-Wajs, Biomolecular investigation of human substantia
nigra in Parkinson's disease by synchrotron radiation Fourier transform infrared
microspectroscopy, Arch. Biochem. Biophys. 459 (2007) 241–248.
[14] M. Bonda, V. Perrin, B. Vileno, H. Runne, A. Kretlow, L. Forro, R. Luthi-Carter, L.M.
Miller, S. Jeney, Synchrotron infrared microspectroscopy detecting the evolution
of Huntington's disease neuropathology and suggesting unique correlates of dys-
function in white versus gray brain matter, Anal. Chem. 83 (2011) 7712–7720.[15] M.W. Bourassa, The involvement of metal ions in copper-zinc superoxide dismutase
related amyotrophic lateral sclerosis, Chemistry, Stony Brook University, Stony
Brook, 2012.
[16] J. Kneipp, L.M. Miller, S. Spassov, F. Sokolowski, P. Lasch, M. Beekes, D. Naumann,
Scrapie-infected cells, isolated prions, and recombinant prion protein: a compar-
ative study, Biopolymers 74 (2004) 163–167.
[17] A. Kretlow, Q. Wang, M. Beekes, D. Naumann, L.M. Miller, Changes in protein
structure and distribution observed at pre-clinical stages of scrapie pathogenesis,
Biochim. Biophys. Acta 1782 (2008) 559–565.
[18] A. Kretlow, Q. Wang, J. Kneipp, P. Lasch, M. Beekes, L. Miller, D. Naumann,
FTIR-microspectroscopy of prion-infected nervous tissue, Biochim. Biophys. Acta
1758 (2006) 948–959.
[19] H. Susi, D.M. Byler, Protein structure by Fourier transform infrared spectroscopy:
second derivative spectra, Biochem. Biophys. Res. Commun. 115 (1983) 391–397.
[20] J.L. Arrondo, A.Muga, J. Castresana, F.M. Goni, Quantitative studies of the structure of
proteins in solution by Fourier-transform infrared spectroscopy, Prog. Biophys. Mol.
Biol. 59 (1993) 23–56.
[21] J.A. Hering, P.R. Innocent, P.I. Haris, Neuro-fuzzy structural classiﬁcation of proteins for
improved protein secondary structure prediction, Proteomics 3 (2003) 1464–1475.
[22] J.A. Hering, P.R. Innocent, P.I. Haris, Towards developing a protein infrared spectra
databank (PISD) for proteomics research, Proteomics 4 (2004) 2310–2319.
[23] M. Severcan, P.I. Haris, F. Severcan, Using artiﬁcially generated spectral data to
improve protein secondary structure prediction from Fourier transform infrared
spectra of proteins, Anal. Biochem. 332 (2004) 238–244.
[24] P. Juszczyk, A.S. Kolodziejczyk, Z. Grzonka, FTIR spectroscopic studies on aggrega-
tion process of the beta-amyloid 11–28 fragment and its variants, J. Pept. Sci. 15
(2009) 23–29.
[25] K. Ii, The role of beta-amyloid in the development of Alzheimer's disease, Drugs
Aging 7 (1995) 97–109.
[26] C.J. Barrow, A. Yasuda, P.T. Kenny, M.G. Zagorski, Solution conformations and ag-
gregational properties of synthetic amyloid beta-peptides of Alzheimer's disease.
Analysis of circular dichroism spectra, J. Mol. Biol. 225 (1992) 1075–1093.
[27] C.J. Barrow, M.G. Zagorski, Solution structures of beta peptide and its constituent
fragments: relation to amyloid deposition, Science 253 (1991) 179–182.
[28] S. Zhang, K. Iwata, M.J. Lachenmann, J.W. Peng, S. Li, E.R. Stimson, Y. Lu, A.M. Felix,
J.E. Maggio, J.P. Lee, The Alzheimer's peptide a beta adopts a collapsed coil struc-
ture in water, J. Struct. Biol. 130 (2000) 130–141.
[29] S. Zhang, A. Rich, Direct conversion of an oligopeptide from a beta-sheet to an alpha-
helix: a model for amyloid formation, Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 23–28.
[30] S.A. Petty, S.M. Decatur, Experimental evidence for the reorganization of
beta-strands within aggregates of the Abeta(16–22) peptide, J. Am. Chem. Soc.
127 (2005) 13488–13489.
[31] E. Cerf, R. Sarroukh, S. Tamamizu-Kato, L. Breydo, S. Derclaye, Y.F. Dufrene, V.
Narayanaswami, E. Goormaghtigh, J.M. Ruysschaert, V. Raussens, Antiparallel
beta-sheet: a signature structure of the oligomeric amyloid beta-peptide, Biochem.
J. 421 (2009) 415–423.
[32] H. Komatsu, L. Liu, I.V. Murray, P.H. Axelsen, A mechanistic link between oxidative
stress and membrane mediated amyloidogenesis revealed by infrared spectros-
copy, Biochim. Biophys. Acta 1768 (2007) 1913–1922.
[33] V. Koppaka, P.H. Axelsen, Accelerated accumulation of amyloid beta proteins on
oxidatively damaged lipid membranes, Biochemistry 39 (2000) 10011–10016.
[34] J. Berriman, L.C. Serpell, K.A. Oberg, A.L. Fink, M. Goedert, R.A. Crowther, Tau ﬁla-
ments from human brain and from in vitro assembly of recombinant protein
show cross-beta structure, Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 9034–9038.
[35] S. Barghorn, P. Davies, E. Mandelkow, Tau paired helical ﬁlaments from
Alzheimer's disease brain and assembled in vitro are based on beta-structure in
the core domain, Biochemistry 43 (2004) 1694–1703.
[36] J. Schmitt, M. Beekes, A. Brauer, T. Udelhoven, P. Lasch, D. Naumann, Identiﬁcation
of scrapie infection from blood serum by Fourier transform infrared spectroscopy,
Anal. Chem. 74 (2002) 3865–3868.
[37] P. Lasch, J. Schmitt, M. Beekes, T. Udelhoven, M. Eiden, H. Fabian, W. Petrich, D.
Naumann, Antemortem identiﬁcation of bovine spongiform encephalopathy
from serum using infrared spectroscopy, Anal. Chem. 75 (2003) 6673–6678.
[38] P. Lasch, M. Beekes, J. Schmitt, D. Naumann, Detection of preclinical scrapie from
serum by infrared spectroscopy and chemometrics, Anal. Bioanal. Chem. 387
(2007) 1791–1800.
[39] A. Thomzig, S. Spassov, M. Friedrich, D. Naumann, M. Beekes, Discriminating scra-
pie and bovine spongiform encephalopathy isolates by infrared spectroscopy of
pathological prion protein, J. Biol. Chem. 279 (2004) 33847–33854.
[40] K.A. Conway, J.D. Harper, P.T. Lansbury Jr., Fibrils formed in vitro from
alpha-synuclein and two mutant forms linked to Parkinson's disease are typical
amyloid, Biochemistry 39 (2000) 2552–2563.
[41] N.P. Ulrih, C.H. Barry, A.L. Fink, Impact of Tyr to Ala mutations on alpha-synuclein ﬁ-
brillation and structural properties, Biochim. Biophys. Acta 1782 (2008) 581–585.
[42] G. Yamin, L.A. Munishkina, M.A. Karymov, Y.L. Lyubchenko, V.N. Uversky, A.L.
Fink, Forcing nonamyloidogenic beta-synuclein to ﬁbrillate, Biochemistry 44
(2005) 9096–9107.
[43] V.N. Uversky, J. Li, P. Souillac, I.S. Millett, S. Doniach, R. Jakes, M. Goedert, A.L. Fink,
Biophysical properties of the synucleins and their propensities to ﬁbrillate: inhi-
bition of alpha-synuclein assembly by beta- and gamma-synucleins, J. Biol. Chem.
277 (2002) 11970–11978.
[44] M.A. Poirier, H. Li, J. Macosko, S. Cai, M. Amzel, C.A. Ross, Huntingtin spheroids
and protoﬁbrils as precursors in polyglutamine ﬁbrilization, J. Biol. Chem. 277
(2002) 41032–41037.
[45] W. Duncan, G.P. Williams, Infrared synchrotron radiation from electron storage
rings, Appl. Opt. 22 (1983) 2914–2923.
2346 L.M. Miller et al. / Biochimica et Biophysica Acta 1828 (2013) 2339–2346[46] G.L. Carr, J.A. Reffner, G.P.Williams, Performance of an infraredmicrospectrometer at
the NSLS, Rev. Sci. Instrum. 66 (1995) 1490–1492.
[47] J.A. Reffner, P.A. Martoglio, G.P. Williams, Fourier transform infrared microscopi-
cal analysis with synchrotron radiation: the microscope optics and system perfor-
mance, Rev. Sci. Instrum. 66 (1995) 1298.
[48] B. Strodel, J.W. Lee, C.S. Whittleston, D.J. Wales, Transmembrane structures for
Alzheimer's Abeta(1–42) oligomers, J. Am. Chem. Soc. 132 (2010) 13300–13312.
[49] H.Y. Kim, M.K. Cho, A. Kumar, E. Maier, C. Siebenhaar, S. Becker, C.O. Fernandez, H.A.
Lashuel, R. Benz, A. Lange, M. Zweckstetter, Structural properties of pore-forming
oligomers of alpha-synuclein, J. Am. Chem. Soc. 131 (2009) 17482–17489.
[50] A. Peralvarez-Marin, A. Barth, A. Graslund, Time-resolved infrared spectroscopy of
pH-induced aggregation of the Alzheimer Abeta(1–28) peptide, J. Mol. Biol. 379
(2008) 589–596.
[51] G.L. Carr, O. Chubar, P. Dumas, Multichannel detection with a synchrotron light
source: design and potential, in: R. Bhargava, I.W. Levin (Eds.), Spectrochemical
Analysis Using Infrared Detectors, Blackwell Publishing, 2006, pp. 56–84.
[52] M.J. Nasse, M.J. Walsh, E.C. Mattson, R. Reininger, A. Kajdacsy-Balla, V. Macias, R.
Bhargava, C.J. Hirschmugl, High-resolution Fourier-transform infrared chemical
imaging with multiple synchrotron beams, Nat. Methods 8 (2011) 413–416.
[53] M.J. Nasse, S. Ratti, M. Giordano, C.J. Hirschmugl, Demountable liquid/ﬂow cell for
in vivo infrared microspectroscopy of biological specimens, Appl. Spectrosc. 63
(2009) 1181–1186.
[54] G. Birarda, G. Grenci, L. Businaro, B.Marmiroli, S. Pacor, F. Piccirilli, L. Vaccari, Infrared
microspectroscopy of biochemical response of living cells in microfabricated de-
vices, Vib. Spectrosc. 53 (2010) 6–11.
[55] H.-Y.N. Holman, R. Miles, Z. Hao, E. Wozei, L.M. Anderson, H. Yang, Real-time chem-
ical imaging of bacterial activity in bioﬁlms using open-channel microﬂuidics and
synchrotron FTIR spectromicroscopy, Anal. Chem. 81 (2009) 8564–8570.
[56] M. Tobin, L. Puskar, R. Barber, E. Harvey, P. Heraud, B. Wood, K. Bambery, C. Dillon,
K. Munro, FTIR spectroscopy of single live cells in aqueous media by synchrotron
IR microscopy using microfabricated sample holders, Vib. Spectrosc. 53 (2010)
34–38.
[57] M.K. Kuimova, K.L. Chan, S.G. Kazarian, Chemical imaging of live cancer cells in
the natural aqueous environment, Appl. Spectrosc. 63 (2009) 164–171.[58] W.Y. Yang, X.L. Xiao, J. Tan, Q.Y. Cai, In situ evaluation of breast cancer cell growth
with 3D ATR-FTIR spectroscopy, Vib. Spectrosc. 49 (2009) 64–67.
[59] C.G. Mariangela, Y. Seydou, S. Diego, C. Sabine, M. Augusto, P. Cyril, Experimental ATR
device for real-time FTIR imaging of living cells using brilliant synchrotron radiation
sources, Biotechnol. Adv. (in press), http://dx.doi.org/10.1016/j.biotechadv.2011.11.
009.
[60] O. Abel, ALS Online Genetic Database, ALSOD (3.0), 2012.
[61] C.M. Lill, O. Abel, L. Bertram, A. Al-Chalabi, Keeping up with genetic discoveries in
amyotrophic lateral sclerosis: the ALSoD and ALSGene databases, Amyotroph.
Lateral Scler. 12 (2011) 238–249.
[62] S.M. Lynch, S.A. Boswell, W. Colón, Kinetic stability of Cu/Zn superoxide
dismutase is dependent on its metal ligands: implications for ALS†, Biochemistry
43 (2004) 16525–16531.
[63] B.F. Shaw, H.L. Lelie, A. Durazo, A.M. Nersissian, G. Xu, P.K. Chan, E.B. Gralla, A. Tiwari,
L.J. Hayward, D.R. Borchelt, Detergent-insoluble aggregates associated with
amyotrophic lateral sclerosis in transgenic mice contain primarily full-length,
unmodiﬁed superoxide dismutase-1, J. Biol. Chem. 283 (2008) 8340–8350.
[64] H.L. Lelie, A. Liba, M.W. Bourassa, M. Chattopadhyay, P.K. Chan, E.B. Gralla, L.M.
Miller, D.R. Borchelt, J.S. Valentine, J.P. Whitelegge, Copper and zinc metallation
status of copper-zinc superoxide dismutase from amyotrophic lateral sclerosis
transgenic mice, J. Biol. Chem. 286 (2011) 2795–2806.
[65] Z.A. Oztug Durer, J.A. Cohlberg, P. Dinh, S. Padua, K. Ehrenclou, S. Downes, J.K. Tan,
Y. Nakano, C.J. Bowman, J.L. Hoskins, C. Kwon, A.Z. Mason, J.A. Rodriguez, P.A.
Doucette, B.F. Shaw, J.S. Valentine, Loss of metal ions, disulﬁde reduction and mu-
tations related to familial ALS promote formation of amyloid-like aggregates from
superoxide dismutase, PLoS One 4 (2009) e5004.
[66] M. Chattopadhyay, A. Durazo, S. Sohn, C. Strong, E. Gralla, J. Whitelegge, J. Valentine,
Initiation and elongation in ﬁbrillation of ALS-linked superoxide dismutase,
Proc. Natl. Acad. Sci. 105 (2008) 18663.
[67] M. Prudencio, P.J. Hart, D.R. Borchelt, P.M. Andersen, Variation in aggregation pro-
pensities among ALS-associated variants of SOD1: correlation to human disease,
Hum. Mol. Genet. 18 (2009) 3217–3226.
[68] M. Prudencio, D.R. Borchelt, Superoxide dismutase 1 encoding mutations linked
to ALS adopts a spectrum of misfolded states, Mol. Neurodegener. 6 (2011) 1–19.
